<DOC>
	<DOC>NCT02864355</DOC>
	<brief_summary>The objective of this prospective, randomized controlled study is to ascertain whether the perioperative use of the FloTrac device to guide fluid and vasopressor management during esophagectomy improves patient outcomes. The primary outcome is cardiopulmonary complications; however, the secondary outcome of decreasing patient morbidity (acute renal injury, anastomotic leak, and overall length of both ICU (intensive care unit) and hospital stay.</brief_summary>
	<brief_title>Does Perioperative Goal Directed Therapy Using Flotrac Improve Outcomes in Esophagectomy Patients</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>Patients 18 years of age or older Patients undergoing primary resection of esophageal cancer and resultant esophagectomy. Patients &lt; 55kg or &gt; 140 kg, based on literature regarding accuracy of FloTrac. Patients with sustained preoperative dysrhythmias, based on literature regarding accuracy of FloTrac (atrial flutter and/or atrial fibrillation). Patients with diagnosed NYHA class IIIIV failure or documented EF &lt; 30% Patients who are unable/unwilling to consent for study procedures</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>